

SECTION 708A CLEANSING STATEMENT AND APPENDIX 3B

ACN 132 204 561 ABN 68 132 204 561

8-12 Alma Road, St Kilda Vic 3182

Contact:

Phone: 1300 289 697 Fax: +61 (0)3 9686 8881

Board of Directors:

Matthew Driscoll, Non- Exec Chairman Cameron Fisher, Executive Director Peter Butterss, Non-Exec Director Paul Spottiswood, Non-Exec Director Stephen Moulton, Non-Exec Director

Chief Executive Officer:

Colin Keating

Company Secretary:

Melanie Leydin

Securities on Issue:

BMP: 67,452,529 ordinary shares

Website: http://www.buymyplace.com.au This notice is given by buyMyplace.com.au Limited (**Company**) under Section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

- (a) the Company has issued 3,125,000 fully paid ordinary shares
 (Shares) at an issue price of \$0.16 (16 cents) per Share, pursuant to the placement to sophisticated and professional investors and the CEO of the Company as announced on 21 November 2017.
- (b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (c) the Company is providing this notice under paragraph 5(e) of section 708A of the Corporations Act;
- (d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:
 - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (ii) section 674 of the Corporations Act as it applies to the Company; and
- (e) as at the date of this announcement, there is no excluded information of the type referred to in Sections 708A(7) and 708A(8) of the Corporations Act.

On behalf of the Board:

Melanie Leydin Company Secretary buyMyplace.com.au Limited

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

buyMyplace.com.au Limited

ABN

68 132 204 561

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1	*Class of *securities issued or to be issued	Fully paid ordinary shares
2	Number of ⁺ securities issued or to be issued (if known) or maximum number which may be issued	3,125,000 Fully paid ordinary shares
3	Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)	Fully paid ordinary shares

⁺ See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	Yes – the shares issued will rank equally in all respects with all ordinary shares currently on issue.
	 If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	
5	Issue price or consideration	Issue price of \$0.16 (16 cents) per share
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Placement to sophisticated and professional investors and the CEO of the Company in accordance with the announcement dated 21 November 2017. The proceeds from the placement will strengthen the balance sheet and provide buyMyplace with the financial flexibility to implement its strategic plan, and continue the funding of the disruption to the real estate industry.
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the</i> ⁺ securities <i>the subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	24 November 2017
6c	Number of +securities issued without security holder approval under rule 7.1	3,125,000 Fully paid ordinary shares
6d	Number of ⁺ securities issued with security holder approval under rule 7.1A	Nil

⁺ See chapter 19 for defined terms.

- 6e Number of *securities issued Nil with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.
- 6h If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and *class of all *securities quoted on ASX (*including* the *securities in section 2 if applicable)

Nil

N/A

N/A

See Annexure 1

8 December 2017

Number +Class 55,982,194 Fully paid ordinary shares 10,886,560 Fully paid ordinary shares - subject to 24 months escrow 583,775 Fully paid ordinary shares - subject to 12 months voluntarv escrow

⁺ See chapter 19 for defined terms.

9

	Number	+Class
Number and ⁺ class of all ⁺ securities not quoted on ASX (<i>including</i> the ⁺ securities in section 2 if applicable)	2,500,000	Director options exercisable at \$0.25 on or before 28 February 2021
	2,500,000	Director options exercisable at \$0.30 on or before 28 February 2021
	2,500,000	Director options exercisable at \$0.35 on or before 28 February 2021
	1,600,000	Employee options exercisable at \$0.25 on or before 28 February 2021
	1,600,000	Employee options exercisable at \$0.30 on or before 28 February 2021
	1,600,000	Employee options exercisable at \$0.35 on or before 28 February 2021
	625,000	Options exercisable at \$0.25 on or before 28 February 2021
	625,000	Options exercisable at \$0.30 on or before 28 February 2021
	625,000	Options exercisable at \$0.35 on or before 28 February 2021
	300,000	Employee options exercisable at \$0.25 on or before 9 August 2021
	300,000	Employee options exercisable at \$0.45 on or before 26 May 2022

⁺ See chapter 19 for defined terms.

9	Number and +class of all	[
Ū	*securities not quoted on ASX (<i>including</i> the *securities in section 2 if applicable)	300,000	Employee options exercisable at \$0.50 on or before 26 May 2022
		300,000	Employee options exercisable at \$0.55 on or before 26 May 2022
		350,000	Employee options exercisable at \$0.45 on or before 13 June 2022
		350,000	Employee options exercisable at \$0.50 on or before 13 June 2022
		350,000	Employee options exercisable at \$0.55 on or before 13 June 2022
		1,875,000	Performance Rights Tranche 1, expiring 30 June 2019 - subject to 24 month escrow
		1,875,000	Performance Rights Tranche 2, expiring 30 June 2019 – subject to 24 month escrow
		1,875,000	Performance Rights Tranche 3, expiring 30 June 2019 – subject to 24 month escrow
		600,000	Performance Rights Tranche 1, expiring 30 June 2019
		600,000	Performance Rights Tranche 2, expiring 30 June 2019
		600,000	Performance Rights Tranche 3, expiring 30 June 2019
		625,000	Performance Rights (B) Tranche 1, expiring 30 June 2019 - subject to 24 month escrow

⁺ See chapter 19 for defined terms.

625,000	Performance Rights (B) Tranche 2, expiring 30 June 2019 – subject to 24 month escrow
625,000	Performance Rights (B) Tranche 3, expiring 30 June 2019 – subject to 24 month escrow
650,000	Performance Rights, Tranche 1
650,000	Performance Rights, Tranche 2
650,000	Performance Rights, Tranche 3

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Part 2 - Pro rata issue

11	ls security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the +securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	⁺ Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A

⁺ See chapter 19 for defined terms.

N/A 18 Names of countries in which the entity has security holders who will not be sent new offer documents

> Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.

- 19 Closing date for receipt of acceptances or renunciations
- 20 Names of any underwriters
- 21 Amount of any underwriting fee N/A or commission
- 22 Names of any brokers to the issue
- 23 Fee or commission payable to the broker to the issue
- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
- 25 If the issue is contingent on security holders' approval, the date of the meeting
- 26 entitlement Date and acceptance form and offer documents will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do security holders sell their entitlements in full through a broker?
- N/A
- How do security holders sell part N/A 31

N/A

⁺ See chapter 19 for defined terms.

	of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*lssue date	N/A

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of +securities (*tick one*)

(b)

(a) +Securities described in Part 1

All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	\square	A copy of any trust deed for the additional +securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A	
39	*Class of *securities for which quotation is sought	N/A	
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	 If the additional *securities do not rank equally, please state: the date from which they do the extent to which they garticipate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	N/A	
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Novechar	
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	Number N/A	+Class N/A

⁺ See chapter 19 for defined terms.

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those +securities should not be granted +quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

MELANIE LEYDIN Company Secretary

8 December 2017

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:		
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 	-	
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	-	
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 	-	
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	22 December 2016 – Right Issue – 8,451,192 13 January 2017 – Exercise of options – 150,000 583,775 fully paid ordinary shares – subject to 12 months voluntary escrow – 28 July 2017	
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	-	
"A"	64,327,529	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	
"B"	0.15 [Note: this value cannot be changed]
<i>Multiply</i> "A" by 0.15	9,649,129
Step 3: Calculate "C", the amount of p has already been used	placement capacity under rule 7.1 that
<i>Insert</i> number of *equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	
Under an exception in rule 7.2	8 December 2017 – Placement – 3,125,000
Under rule 7.1A	
• With security holder approval under rule 7.1 or rule 7.4	
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 	
"C"	3,125,000
Step 4: Subtract "C" from ["A" x "B"] capacity under rule 7.1	to calculate remaining placement
"A" x 0.15	9,649,129
Note: number must be same as shown in Step 2	
Subtract "C"	3,125,000
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.15] – "C"	6,524,129
	Note: this is the remaining placement capacity under rule 7.1

⁺ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entitiesStep 1: Calculate "A", the base figure from which the placement capacity is
calculated"A"64,327,529Note: number must be same as shown in Step 1
of Part 164,327,529Step 2: Calculate 10% of "A""D"0.10
Note: this value cannot be changedMultiply "A" by 0.106,432,753Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that
has already been used

-		
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		-
/ • •	Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line	
61	items 'E"	-

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10 Note: number must be same as shown in Step 2	6,432,753
Subtract "E" Note: number must be same as shown in Step 3	-
<i>Total</i> ["A" x 0.10] – "E"	6,432,753 Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.